Drug Profile
Rucaparib companion diagnostic - Clovis Oncology/Foundation Medicine
Alternative Names: CDxBRCA; FoundationFocus CDxBRCA; FoundationOne Liquid CDx; FoundationOneLiquid CDx; Rubraca companion diagnosticLatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Clovis Oncology; Foundation Medicine
- Developer Clovis Oncology [CEASED]; Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ovarian cancer
- Registered Prostate cancer
- Phase III Fallopian tube cancer; Peritoneal cancer
Most Recent Events
- 30 Dec 2022 Rucaparib companion diagnostic is still in registered trial for Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in USA (Foundation Medicine pipeline, December 2022)
- 27 Oct 2020 US FDA approves rucaparib companion diagnostic for the diagnosis of advanced Ovarian cancer
- 26 Aug 2020 Registered for Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in USA (unspecified route)